Koers Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE
Aandelen
TEVA
IL0006290147
Farmaceutische producten
Omzet 2024 * | 16 mld. 58,09 mld. 14,71 mld. | Omzet 2025 * | 16,62 mld. 60,36 mld. 15,28 mld. | Marktkapitalisatie | 19,34 mld. 70,23 mld. 17,79 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 809 mln. 2,94 mld. 744 mln. | Nettowinst (verlies) 2025 * | 1,38 mld. 4,99 mld. 1,26 mld. | EV/omzet 2024 * | 2,15 x |
Nettoschuld 2024 * | 14,98 mld. 54,39 mld. 13,77 mld. | Nettoschuld 2025 * | 12,44 mld. 45,18 mld. 11,44 mld. | EV/omzet 2025 * | 1,91 x |
K/w-verhouding 2024 * |
17,8
x | K/w-verhouding 2025 * |
12,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 90,93% |
Recentste transcriptie over Teva Pharmaceutical Industries Limited
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 01-01-23 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 22-12-19 |
Kathleen Veit
CMP | Compliance Officer | - | 01-01-10 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 01-09-15 |
Janet Vergis
BRD | Director/Board Member | 59 | 09-06-20 |
Sol Barer
CHM | Chairman | 76 | 01-01-15 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+62,99% | 856 mld. | |
+39,42% | 631 mld. | |
-4,61% | 359 mld. | |
+17,53% | 325 mld. | |
+8,44% | 297 mld. | |
+5,52% | 234 mld. | |
+16,38% | 226 mld. | |
+14,23% | 177 mld. | |
+1,93% | 165 mld. |